- Home>
- Journal Watch
- >
- osteoporosis
Search for osteoporosis in all Journal Watch editions
Physician-authored summaries on the latest research on osteoporosis, editorials on osteoporosis, and perspectives on osteoporosis - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 527 results - Relevance
- Date
You searched for: osteoporosis
-
Cost-Effectiveness of Various Screening Strategies for Osteoporosis
- January 17, 2012
- Jamaluddin Moloo, MD, MPH
- General Medicine
A modeling analysis favored initial screening at age 55.- Reviewing:
- Nayak S et al., Ann Intern Med 2011 Dec 6; 155:751. Schousboe JT and Gourlay ML., Ann Intern Med 2011 Dec 6; 155:788.
-
Clinicians Don't Always Follow Guidelines for Osteoporosis Free
- November 10, 2011
- Andrew M. Kaunitz, MD
- Women's Health
Many women receive inappropriate screening and treatment.
CME Exam- Reviewing:
- Schnatz PF et al., Menopause 2011 Oct; 18:1072.
-
Low Dietary Calcium Intake Raises Risk for Fracture and Osteoporosis
- July 19, 2011
- Paul S. Mueller, MD, MPH, FACP
- General Medicine
During 19 years, first fracture of any type was significantly more common among women with low daily dietary calcium intake (≤750 mg).
CME Exam- Reviewing:
- Warensjö E et al., BMJ 2011 May 24; 342:d1473.
-
Nitroglycerin for Osteoporosis?
- March 10, 2011
- Andrew M. Kaunitz, MD
- Women's Health
A Canadian trial showed favorable skeletal effects, but headaches are a concern.
CME Exam- Reviewing:
- Jamal SA et al., JAMA 2011 Feb 23; 305:800. Khosla S., JAMA 2011 Feb 23; 305:826.
-
Providing Absolute Fracture Risk Affects Osteoporosis Medication Initiation
- January 4, 2011
- Jamaluddin Moloo, MD, MPH
- General Medicine
Before reporting of 10-year fracture risk, more women received osteoporosis medications.- Reviewing:
- Leslie WD et al., Ann Intern Med 2010 Nov 2; 153:580.
-
New Selective Estrogen-Receptor Modulator for Treating Women with Osteoporosis?
- February 24, 2010
- Andrew M. Kaunitz, MD
- Women's Health
Lasofoxifene is unlikely to offer net benefits greater than those of existing therapies.- Reviewing:
- Cummings SR et al., N Engl J Med 2010 Feb 25; 362:686. Becker C., N Engl J Med 2010 Feb 25; 362:752.
-
2010 NAMS Recommendations for Managing Osteoporosis in Postmenopausal Women Free
- February 18, 2010
- Diane E. Judge, APN/CNP
- Women's Health
Updates to the 2006 recommendations incorporate new findings.
CME Exam- Reviewing:
- Bonnick SL et al., Menopause 2010 Jan/Feb; 17:25.
-
Possible New Option for Treating Osteoporosis Free
- August 20, 2009
- Allan S. Brett, MD
- General Medicine
Both men who were receiving androgen-deprivation therapy and postmenopausal women gained bone density with denosumab.
CME Exam- Reviewing:
- Cummings SR et al., N Engl J Med 2009 Aug 20; 361:756. Smith MR et al., N Engl J Med 2009 Aug 20; 361:745. Khosla S., N Engl J Med 2009 Aug 20; 361:818.
-
A New Agent for Postmenopausal Osteoporosis? Free
- August 11, 2009
- Andrew M. Kaunitz, MD
- Women's Health
Biannual subcutaneous denosumab injections prevented vertebral, nonvertebral, and hip fractures.- Reviewing:
- Cummings SR et al., N Engl J Med 2009 Aug 20; 361:756. Khosla S., N Engl J Med 2009 Aug 20; 361:818.
-
Osteoporosis and Fracture in Men with Prostate Cancer
- August 11, 2009
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Denosumab increased bone-mineral density and lowered fracture incidence in men receiving androgen-deprivation therapy for nonmetastatic disease.- Reviewing:
- Smith MR et al., N Engl J Med 2009 Aug 20; 361:745. Khosla S., N Engl J Med 2009 Aug 20; 361:818.
-
Osteoporosis and Benign Positional Vertigo
- June 30, 2009
- Robert W. Baloh, MD
- Neurology
Osteoporosis might be the cause of recurrent bouts of BPV.- Reviewing:
- Jeong SH et al., Neurology 2009 Mar 24; 72:1069.
-
Osteoporosis: Another Risk for Patients with Psoriasis?
- March 13, 2009
- Jeffrey P. Callen, MD
- Dermatology
In men, psoriasis was significantly associated with an increased risk for decreased bone-mineral density.- Reviewing:
- Dreiher J et al., J Invest Dermatol 2009 Jan 22;:
-
Proton-Pump Inhibitors and Osteoporosis-Related Fracture
Use of PPI therapy for 7 years or longer is associated with excess risk for osteoporosis-related fractures.- Reviewing:
- Targownik LE et al., CMAJ 2008 Aug 12; 179:319.
-
Use of Proton-Pump Inhibitors Is Associated with Excess Risk for Osteoporosis-Related Fractures
- September 16, 2008
- Paul S. Mueller, MD, MPH, FACP
- General Medicine
Notably, continuous PPI use for =5 years was associated with significant excess risk for hip fracture.
Audio Interview- Reviewing:
- Targownik LE et al., CMAJ 2008 Aug 12; 179:319.
-
Guideline for Osteoporosis Screening in Men
- June 12, 2008
- Richard Saitz, MD, MPH, FACP, FASAM
- General Medicine
Testing is recommended for men at increased risk.
Audio Interview- Reviewing:
- Qaseem A et al., Ann Intern Med 2008 May 6; 148:680. Liu H et al., Ann Intern Med 2008 May 6; 148:685.
-
A New Approach to Osteoporosis and Fracture Risk
- April 8, 2008
- Allan S. Brett, MD
- General Medicine
A new statistical model predicts 10-year risk for hip and other major fractures.- Reviewing:
- Tosteson ANA et al., Osteoporos Int 2008 Apr; 19:437. Dawson-Hughes B et al., Osteoporos Int 2008 Apr; 19:449. Siris E and Delmas PD., Osteoporos Int 2008 Apr; 19:383.
-
Parathyroid Hormone vs. Alendronate for Steroid-Induced Osteoporosis
- November 27, 2007
- Allan S. Brett, MD
- General Medicine
Parathyroid hormone was associated with significantly greater increases in BMD and fewer vertebral fractures — but not nonvertebral fractures.- Reviewing:
- Saag KG et al., N Engl J Med 2007 Nov 15; 357:2028.
-
Biologic Therapy Apparently More Effective Than Oral Therapy for Glucocorticoid-Associated Osteoporosis
- November 14, 2007
- Jeffrey P. Callen, MD
- Dermatology
Teriparatide was associated with greater bone density and fewer vertebral fractures in corticosteroid recipients, but the therapy is costly.- Reviewing:
- Saag KG et al., N Engl J Med 2007 Nov 15; 357:2028.
-
Once-Yearly Treatment for Osteoporosis? Free
- May 2, 2007
- Allan S. Brett, MD
- General Medicine
With a single yearly IV infusion of zoledronic acid, bones increased in density, and fractures were fewer.- Reviewing:
- Black DM et al., N Engl J Med 2007 May 3; 356:1809-22.
-
Recombinant PTH May Prevent Vertebral Fractures in Osteoporosis
- March 22, 2007
- Richard Saitz, MD, MPH, FACP, FASAM
- General Medicine
However, gains with PTH were modest, and side effects were common.- Reviewing:
- Greenspan SL et al., Ann Intern Med 2007 Mar 6; 146:326-39.
Sort by:
Items 1 to 20 of 527 results - Relevance
- Date
